Incidence and severity of immune-related hepatitis after dual checkpoint therapy is linked to younger age independent of herpes virus immunity.

Zhen ZhangDavid Rafei-ShamsabadiSaskia LehrNico BuettnerRebecca DiehlDaniela HuzlyDavid J PinatoRobert ThimmeFrank MeissBertram Bengsch

Published in: Journal of translational medicine (2022)

Younger age more accurately predicts ICB-hepatitis after anti-PD-1&anti-CTLA4 checkpoint therapy at baseline compared to herpes virus serology or TEM subsets. Younger patients should be carefully monitored for the development of ICB-hepatitis.

Keyphrases

end stage renal disease
dna damage
cell cycle
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
risk factors
cell proliferation
peripheral blood
oxidative stress
bone marrow